Circulation Heart Failure,
Journal Year:
2010,
Volume and Issue:
4(1), P. 8 - 17
Published: Oct. 30, 2010
In
heart
failure
(HF),
a
defective
nitric
oxide
signaling
is
involved
in
left
ventricular
(LV)
diastolic
abnormalities
and
remodeling.
PDE5
inhibition,
by
blocking
degradation
of
second-messenger
cyclic
guanosine
monophosphate,
might
be
beneficial.
cohort
systolic
HF
patients,
we
tested
the
effects
inhibition
(sildenafil)
on
LV
ejection
fraction,
function,
cardiac
geometry,
clinical
status.Forty-five
patients
(New
York
Heart
Association
class
II-III)
were
randomly
assigned
to
placebo
or
sildenafil
(50
mg
three
times
per
day)
for
1
year,
with
assessment
(6
months
year)
cardiopulmonary
exercise
performance,
quality
life.
group
only,
at
6
early
tissue
Doppler
velocities
(E')
mitral
lateral
(from
4.62
5.20
5.19
m/s)
septal
4.71
5.23
5.24
annuli
significantly
increased,
whereas
ratio
transmitral
(E)
E'
decreased
13.1
9.8
9.4)
(P<0.01).
Changes
accompanied
reverse
remodeling
atrial
volume
index
32.0
29.0
29.1
mL/m(2);
P<0.01)
mass
148.0
130.0
128.0
g/m(2);
P<0.01).
Furthermore,
improved
performance
(peak
Vo(2)),
ventilation
efficiency
(ventilation
CO(2)
production
slope),
life
Minor
adverse
noted:
flushing
4
headache
2
treated
patients.Findings
confirm
that
HF,
improves
functional
capacity
status
provide
first
human
evidence
function
geometry
are
additional
targets
benefits
related
chronic
inhibition.
Circulation Heart Failure,
Journal Year:
2013,
Volume and Issue:
6(3), P. 606 - 619
Published: April 25, 2013
Background—
Heart
failure
(HF)
is
an
important
contributor
to
both
the
burden
and
cost
of
national
healthcare
expenditures,
with
more
older
Americans
hospitalized
for
HF
than
any
other
medical
condition.
With
aging
population,
impact
expected
increase
substantially.
Methods
Results—
We
estimated
future
costs
by
adapting
a
methodology
developed
American
Association
project
epidemiology
from
2012
2030
without
double
counting
attributed
comorbid
conditions.
The
model
assumes
that
prevalence
will
remain
constant
age,
sex,
race/ethnicity
rising
technological
innovation
continue
at
same
rate.
By
2030,
>8
million
people
in
United
States
(1
every
33)
have
HF.
Between
real
(2010$)
total
direct
are
projected
$21
billion
$53
billion.
Total
costs,
including
indirect
HF,
$31
$70
2030.
If
one
all
cardiac
care
patients
attributable
(no
attribution
conditions),
estimates
treating
be
3-fold
higher
($160
costs).
Conclusions—
markedly
because
population.
Strategies
prevent
improve
efficiency
needed.
Circulation Research,
Journal Year:
2017,
Volume and Issue:
120(3), P. 472 - 495
Published: Feb. 2, 2017
Stroke
is
a
heterogeneous
syndrome,
and
determining
risk
factors
treatment
depends
on
the
specific
pathogenesis
of
stroke.
Risk
for
stroke
can
be
categorized
as
modifiable
nonmodifiable.
Age,
sex,
race/ethnicity
are
nonmodifiable
both
ischemic
hemorrhagic
stroke,
while
hypertension,
smoking,
diet,
physical
inactivity
among
some
more
commonly
reported
factors.
More
recently
described
triggers
include
inflammatory
disorders,
infection,
pollution,
cardiac
atrial
disorders
independent
fibrillation.
Single-gene
may
cause
rare,
hereditary
which
primary
manifestation.
Recent
research
also
suggests
that
common
rare
genetic
polymorphisms
influence
causes
due
to
other
mechanisms,
such
Genetic
factors,
particularly
those
with
environmental
interactions,
than
previously
recognized.
prevention
has
generally
focused
Lifestyle
behavioral
modification,
dietary
changes
or
smoking
cessation,
not
only
reduces
risk,
but
cardiovascular
diseases.
Other
strategies
identifying
treating
medical
conditions,
hypertension
diabetes,
increase
risk.
into
genetics
identified
at
ways
target
at-risk
populations
prevention.
PLoS ONE,
Journal Year:
2014,
Volume and Issue:
9(2), P. e87987 - e87987
Published: Feb. 4, 2014
Background
Physical
therapy
(PT)
is
one
of
the
key
disciplines
in
interdisciplinary
stroke
rehabilitation.
The
aim
this
systematic
review
was
to
provide
an
update
evidence
for
rehabilitation
interventions
domain
PT.
Methods
and
Findings
Randomized
controlled
trials
(RCTs)
regarding
PT
were
retrieved
through
a
search.
Outcomes
classified
according
ICF.
RCTs
with
low
risk
bias
quantitatively
analyzed.
Differences
between
phases
poststroke
explored
subgroup
analyses.
A
best
synthesis
performed
neurological
treatment
approaches.
search
yielded
467
(N
=
25373;
median
PEDro
score
6
[IQR
5–7]),
identifying
53
interventions.
No
adverse
events
reported.
Strong
found
significant
positive
effects
13
related
gait,
11
arm-hand
activities,
1
intervention
ADL,
3
physical
fitness.
Summary
Effect
Sizes
(SESs)
ranged
from
0.17
(95%CI
0.03–0.70;
I2
0%)
therapeutic
positioning
paretic
arm
2.47
0.84–4.11;
77%)
training
sitting
balance.
There
strong
that
higher
dose
practice
better,
SESs
ranging
0.21
0.02–0.39;
6%)
motor
function
0.61
0.41–0.82;
41%)
muscle
strength
leg.
Subgroup
analyses
differences
respect
timing
10
Neurological
approaches
body
functions
activities
showed
equal
or
unfavorable
when
compared
other
Main
limitations
present
are
not
using
individual
patient
data
meta-analyses
absence
correction
multiple
testing.
Conclusions
favoring
intensive
high
repetitive
task-oriented
task-specific
all
poststroke.
Effects
mostly
restricted
actually
trained
activities.
Suggestions
prioritizing
research
given.
Circulation,
Journal Year:
2023,
Volume and Issue:
149(1)
Published: Nov. 30, 2023
The
"2023
ACC/AHA/ACCP/HRS
Guideline
for
the
Diagnosis
and
Management
of
Atrial
Fibrillation"
provides
recommendations
to
guide
clinicians
in
treatment
patients
with
atrial
fibrillation.
